Please login to the form below

Not currently logged in
Email:
Password:

Scott Whitcup joins Questcor’s board of directors

Allergan’s chief scientific officer to help expand Acthar’s use to treat autoimmune conditions

Scott Whitcup - Questcor PharmaceuticalsScott Whitcup, executive VP of R&D and chief scientific officer at Amgen, has joined the board of directors at Questcor Pharmaceuticals.

The company said his experience in commericialising Botox as a treatment for chronic migraine, upper limb spasticity and neurogenic urologic conditions would be beneficial in Questcor's efforts to expand the uses of its own Acthar Gel brand to treat autoimmune conditions.

“The growth strategies and product manufacturing for Acthar and Botox have some interesting parallels,” said Questcor's chair, Virgil Thompson.

Acthar is currently approved in the US in several indications, including infantile spasms; exacerbations of multiple sclerosis in adults; nephrotic syndrome; and several rheumatic disorders including collagen diseases; dermatologic diseases and ophthalmic diseases.

Whitcup joined Allergan in 2000, becoming executive VP of R&D in 2004 and chief scientific officer in 2009.

Other products he has helped bring to market at Allergan include Lumigan, Restasis and Latisse.

Prior to joining Allergan Whitcup served as clinical director at the National Institutes of Health's National Eye Institute, where he help develop new therapies for ophthalmic diseases

22nd February 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...
PANDAS/PANS Awareness: A parent’s story
To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
Iskra Reic
Leading AstraZeneca’s return to growth in Europe
PME talks to Iskra Reic, the company’s head of Europe and Canada...

Infographics